Trump's push for the world's lowest drug prices hits snag with mid-sized companies

Reuters· July 2, 2026

The effort by the Trump administration to achieve the world's lowest drug prices has encountered difficulties involving mid-sized companies. This development suggests that the implementation of broad pricing reforms may face specific resistance within certain segments of the pharmaceutical industry. For the sector, these snags represent potential delays or modifications to proposed pricing models that aim to drastically lower costs.

Read the full story at Reuters

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to Reuters.

More in Pharmaceutical

Senate draft proposal aims to reshape 340B drug pricing program

A new Senate draft proposal has been introduced with the objective of reshaping the 340B drug pricing program, signaling a major move in federal health care reform. This legislative effort focuses on cost-containment and compliance within the pharmaceutical sector, potentially impacting how drug discounts are administered to covered entities. For pharmaceutical stakeholders, these developments represent a critical shift in the regulatory landscape governing drug pricing and market access.

July 2, 2026

Eli Lilly, Cellares and FUJIFILM among "FDA Precheck" pilot winners

Eli Lilly, Cellares and FUJIFILM among "FDA Precheck" pilot winners Cleanroom Technology

July 2, 2026

FDA widens Vertex’s Casgevy use for paediatric patients

The U.S. Food and Drug Administration has expanded the approved use of Vertex Pharmaceuticals’ Casgevy to include pediatric patients. This regulatory update allows for the treatment of younger populations with the therapy, broadening its clinical application. The expansion represents a key development for Vertex as it seeks to increase the reach of its pharmaceutical offerings in the pediatric market.

July 2, 2026

U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug

A federal judge has issued a ruling to block a first-of-its-kind price cap on Amgen's blockbuster drug Enbrel in Colorado. The decision halts a move by the Colorado Prescription Drug Affordability Board to establish an upper payment limit for the medication, which was deemed unaffordable by the state panel. This ruling represents a significant legal victory for the pharmaceutical industry as it challenges state-level efforts to control rising prescription drug costs.

July 2, 2026